Replies to post #324479 on Avid Bioservices Inc (CDMO)

[peregr]

Mologen up 25% on a deal that is lesser in value than the one we received and we are flat, and CDMO shareholders want investigations and class action suits. Guess it depends on perspective.

This is the new business model in personalized therapy, which is where BAVI falls.

When Oncologie goes public, I would be a buyer.